Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Phase 3 KEYNOTE-775 Trial in Advanced Endometrial Cancer

May 4th 2021

Vicky Makker, MD, reviews the trial design and efficacy data for the open-label, randomized phase 3 KEYNOTE-775/Study 309 in patients with advanced endometrial cancer.

Thermal Ablation Shown to Be Safe, Effective Local Treatment in Gynecologic Cancers

April 30th 2021

Thermal ablation was shown to be a safe and effective treatment for patients with localized gynecologic tumors in the lungs, abdomen, and pelvis, according to findings from a retrospective analysis published in the Journal of Vascular and Interventional Radiology.

Dr. Monk on the Clinical Implications of the PRIMA Trial in Advanced Ovarian Cancer

April 29th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the clinical implications of the phase 3 PRIMA trial in newly diagnosed advanced ovarian cancer.

Dr. Miller on the Potential Utility of Sequential PARP Inhibition in Ovarian Cancer

April 27th 2021

Eirwen M. Miller, MD, discusses the potential utility of sequential PARP inhibition in ovarian cancer.

Dostarlimab Approved in Europe for Advanced dMMR Endometrial Cancer

April 23rd 2021

The European Commission has granted conditional marketing authorization to dostarlimab for the treatment of patients with microsatellite instability–high/mismatch repair deficient recurrent or advanced endometrial cancer who have progressed on or following prior therapy with a platinum-containing regimen.

FDA Approves VENTANA MMR RxDx as Companion Diagnostic for Dostarlimab in Endometrial Cancer

April 23rd 2021

The FDA has approved the VENTANA MMR RxDx panel as a companion diagnostic assay to determine eligibility for dostarlimab-gxly as a treatment for patients with advanced or recurrent endometrial cancer whose tumors are mismatch repair deficient.

FDA Approves Dostarlimab for Advanced dMMR Endometrial Cancer

April 22nd 2021

The FDA has granted an accelerated approval to dostarlimab-gxly (Jemperli) for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers are mismatch repair deficient, as determined by an FDA-approved test.

FDA Approval Sought for Balstilimab for Recurrent or Metastatic Cervical Cancer

April 19th 2021

A biologics license application has been submitted to the FDA seeking the accelerated approval of balstilimab for use in the treatment of patients with recurrent or metastatic cervical cancer with disease progression on, or following, chemotherapy.

Combination Strategies Reshape Treatment Paradigm for Advanced Endometrial Cancer

April 19th 2021

As investigators expand their understanding of the biology of endometrial cancer, doors to new treatment approaches are opening, including the use of a variety of combinations that employ targeted therapies and immunotherapies.

Dr. O’Malley on the Results of the KEYNOTE-775 Trial in Endometrial Cancer

April 15th 2021

David M. O'Malley, MD, discusses the results of the phase 3 KEYNOTE-775 trial in advanced endometrial cancer.

Role of Combination I/O in Advanced Endometrial Cancer (EC)

April 14th 2021

Shannon N. Westin, MD, MPH, FACOG, discusses the rationale for the use of combination immunotherapy for advanced and recurrent endometrial cancer.

Dr. Subbiah on the Efficacy of Selpercatinib in RET Fusion–Positive Cancers

April 13th 2021

Vivek Subbiah, MD, discusses outcomes with selpercatinib in patients with RET fusion–positive cancer.

Tislelizumab/Sitravatinib Shows Early Antitumor Activity, Safety in Platinum-Resistant Epithelial Ovarian Cancer

April 11th 2021

The combination of tislelizumab and sitravatinib demonstrated early antitumor activity and a manageable safety profile in patients with recurrent platinum-resistant epithelial ovarian cancer and were naïve to PD-1/PD-L1 inhibition.

TAS-117 Shows Limited Efficacy in Ovarian, Breast Tumors

April 11th 2021

Treatment with TAS-117, a highly potent and selective oral allosteric pan-v-akt murine thymoma viral oncogene homolog inhibitor, demonstrated some clinical efficacy in patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.

Dr. Marron on an Adjuvant Personalized Neoantigen Peptide Vaccine for Several Malignancies

April 10th 2021

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

FDA Grants Priority Review to Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

April 9th 2021

The FDA has granted a priority review to the biologics license application for tisotumab vedotin as a potential treatment for patients with recurrent or metastatic cervical cancer with progressive disease on, or following, chemotherapy.

Pursuing PARP Beyond HRD+ Ovarian Cancer

April 9th 2021

Hye Sook Chon, MD, teases out some of the differences between the data with PARP inhibitors in the frontline maintenance setting and shed light on ongoing research with combinations that could broaden their utility in patients with advanced ovarian cancer.

Utility of HRD Testing in Ovarian Cancer Expands, but Standardization Remains Elusive

April 6th 2021

Thomas C. Krivak, MD, discusses the significance of HRD in ovarian cancer, approved and prospective HRD tests, and considerations for genomic testing in this population.

Study Examines Cost-Sharing Trends in PARP Inhibitors for Ovarian Cancer

April 2nd 2021

Out-of-pocket costs for patients with ovarian cancer who have been treated with PARP inhibitors are generally low, according to recent study results from a single institution.

Dr. Wenham on Future Directions with Antibody-Drug Conjugates in Ovarian Cancer

March 30th 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.